FREE FEDEX 2-DAY SHIPPING OVER $200Same-Day Dispatch Before 1 PM ETThird-Party TestedBatch COAs Available
FOR LABORATORY RESEARCH USE ONLY — NOT FOR HUMAN OR VETERINARY USE
Peptide Pilots
Log in
Mitochondrial biologyComparative literatureBioenergetics

Mitochondrial Research Compounds: MOTS-c, SS-31 and NAD+ in the Published Literature

Three very different molecules get filed under 'mitochondrial'. One is encoded in mitochondrial DNA, one binds an inner-membrane lipid, and one is a redox cofactor. The distinctions matter when reading their studies.

By Samantha Lundqvist, MSc, Biochemistry9 min read

This article summarises published scientific literature for laboratory professionals. It is not medical advice and does not describe human or veterinary use. All materials supplied by Peptide Pilots are for controlled laboratory research only.

Key takeaways

  • MOTS-c, SS-31 and NAD-related reagents are three distinct targets, not one 'mitochondrial' category.
  • Evidence depth differs sharply across the three, with SS-31 carrying the most clinical-stage data and MOTS-c the least.
  • Common measurement pitfalls — assay choice, normalisation and readout timing — explain much of the variability between published reports.

Three targets, not one category

MOTS-c is a short peptide encoded within the mitochondrial 12S rRNA region, described in the literature as a mitochondrial-derived peptide that influences the folate-methionine cycle and AMPK signalling. SS-31 (elamipretide) is a synthetic tetrapeptide that concentrates in the inner mitochondrial membrane through an association with cardiolipin, with reported effects on supercomplex organisation and electron transport efficiency. NAD+ is not a peptide at all: it is a redox cofactor and substrate for sirtuins and PARPs, studied chiefly through its precursors.

Because the three act at different levels — gene-encoded signalling peptide, membrane lipid interaction, and cofactor availability — a result for one carries no inferential weight for the others.

Evidence depth differs sharply

  • SS-31 / elamipretide has the deepest registered clinical record of the three, including trials in primary mitochondrial myopathy and cardiac indications, with mixed endpoint outcomes.
  • MOTS-c is dominated by cell and rodent work, with human data largely observational or exercise-physiology correlational.
  • NAD+ has extensive biochemistry but comparatively limited controlled human outcome data, most of it on precursors rather than the cofactor itself.

A negative or equivocal registered trial is more informative than a positive rodent study, and it is common for the compound with the strongest clinical programme to look least impressive in a summary. That is an artefact of scrutiny, not of biology.

Common measurement pitfalls

Mitochondrial endpoints are unusually method-sensitive. Respirometry values depend on substrate-inhibitor protocols and permeabilisation technique; tissue NAD+ measurements degrade quickly during sampling and vary by extraction chemistry; and AMPK phosphorylation is exquisitely responsive to handling stress in the minutes before tissue collection. When two studies disagree, the methods section is usually the explanation.

Compound pages

Each compound's research library entry lists identifiers, separates in-vitro, animal and human evidence, tabulates the studies with citations and states the limitations of the current record.

Related research

References

  1. Lee, C., et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. View source
  2. Birk, A. V., et al. (2013). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology. View source
  3. Covarrubias, A. J., et al. (2021). NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. View source

Frequently asked questions

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial genome — a so-called mitochondrial-derived peptide — that has been studied in cellular and animal models for effects on metabolism and stress responses. The published work is preclinical, and its physiological role in humans is not established.

SS-31 (also known as elamipretide in the clinical literature) is a synthetic mitochondria-targeted tetrapeptide designed to associate with cardiolipin in the inner mitochondrial membrane. It has a comparatively mature preclinical literature and has been examined in some early clinical studies, though it is not an approved drug.

No. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme, not a peptide — it is included in this article because it appears alongside mitochondrial peptides in the cellular-metabolism research literature, but its chemistry, handling and analytical verification differ from peptide materials.